In this task, you are provided with an article of the legal acts. Your task is to classify it into three categories (Regulation, Decision and Directive) based on its content: 1) Regulation is a binding legislative act that must be applied in its entirety on a set date across all the member states (European Union countries). 2) Decision is binding on those to whom it is addressed (e.g. an European Union country or an individual company) and is directly applicable. 3) Directive is a legislative act that sets out a goal that all  must achieve. However, it is up to the individual countries to devise their own laws on how to reach these goals.

Example Input: Regulation (EEC) No 2742/75 shall be amended as follows:    1. In Article 1 (1) '17 units of account' shall be substituted for '14 units of account';2. In Article 1 (2) '23 units of account' shall be substituted for '20 units of account';3. In Article 1 (3) '20 720 units of account' shall be substituted for '17 720 units of account';4. In Article 2 '17 units of account' shall be substituted for '14 units of account';5. In Article 3 (1) '175 units of account' shall be substituted for '172 units of account';6. In the second paragraph of Article 4 '17 units of account' shall be substituted for '14 units of account';7. Article 5a shall be replaced by the following:'Article 5a1. By way of derogation from Articles 1, 2 and 4 no production refund shall be granted for products destined for the manufacture of isoglucose.2. 'Isoglucose' means the syrup obtained from glucose syrups with a content by weight in the dry state of:    - at least 10 % fructose and- at least 1 % in total of oligosaccharides and polysaccharides.3. In implementation of paragraph 1 the Member States shall recover from manufacturers of isoglucose the amounts referred to in Articles 1 and 2 and the amount obtained in implementing Article 4, depending on the product used in its manufacture.' This Regulation shall enter into force:    - on 1 August 1977 for products covered by Regulation (EEC) No 2727/75,- on 1 September 1977 for products covered by Regulation (EEC) No 1418/76.  (1)OJ No L 281, 1.11.1975, p. 1. (2)OJ No L 158, 29.6.1977, p. 1. (3)OJ No L 166, 25.6.1976, p. 1. (4)OJ No L 136, 2.6.1977, p. 13. (5)OJ No L 281, 1.11.1975, p. 57. (6)OJ No L 206, 31.7.1976, p. 3. (7)OJ No L 134, 28.5.1977, p. 4.This Regulation shall be binding in its entirety and directly applicable in all Member States.
Example Output: Regulation

Example Input: Directive 65/65/EEC is hereby amended as follows:1. Point 8 of the second paragraph of Article 4 shall be replaced by the following text:'8. Results of:- physico-chemical, biological or microbiological tests,- pharmacological and toxicological tests,- clinical trials.However, and without prejudice to the law relating to the protection of industrial and commercial property:(a) The applicant shall not be required to provide the results of pharmacological and toxicological tests or the results of clinical trials if he can demonstrate:(i) either that the proprietary medicinal product is essentially similar to a product authorized in the country concerned by the application and that the person responsible for the marketing of the original proprietary medicinal product has consented to the pharmacological, toxicological or clinical references contained in the file on the original proprietary medicinal product being used for the purpose of examining the application in question;(ii) or by detailed references to published scientific literature presented in accordance with the second paragraph of Article 1 of Directive 75/318/EEC that the constituent or constituents of the proprietary medicinal product have a well established medicinal use, with recognized efficacy and an acceptable level of safety;(iii) or that the proprietary medicinal product is essentially similar to a product which has been authorized within the Community, in accordance with Community provisions in force, for not less than six years and is marketed in the Member State for which the application is made; this period shall be extended to 10 years in the case of high-technology medicinal products within the meaning of Part A in the Annex to Directive 87/22/EEC (1) or of a medicinal product within the meaning of Part B in the Annex to that Directive for which the procedure laid down in Article 2 thereof has been followed; furthermore, a Member State may also extend this period to 10 years by a single Decision covering all the products marketed on its territory where it considers this necessary in the interest of public health. Member States are at liberty not to apply the abovementioned six-year period beyond the date of expiry of a patent protecting the original product.However, where the proprietary medicinal product is intended for a different therapeutic use from that of the other proprietary medicinal products marketed or is to be administered by different routes or in different doses, the results of appropriate pharmacological and toxicological tests and/or of appropriate clinical trials must be provided.(b) In the case of new proprietary medicinal products containing known constituents not hitherto used in combination for therapeutic purposes, the results of pharmacological and toxicological tests and of clinical trials relating to that combination must be provided, but it shall not be necessary to provide references relating to each individual constituent.(1) OJ No L 15, 17. 1. 1987, p. 38.';2. Article 16 is hereby repealed. Member States shall take the measures necessary to comply with this Directive no later than 1 July 1987. They shall forthwith inform the Commission thereof.However, with regard to the Hellenic Republic, the Kingdom of Spain and the Portuguese Republic, the date referred to in the first paragraph shall be replaced by 1 January 1992. This Directive is addressed to the Member States.
Example Output: Directive

Example Input: Having regard to the Royal Decree of 17 February 1978 and the Ministerial Decree of 17 February 1978 the existing provisions for the implementation in Belgium of Title II of Directive 72/161/EEC continue to satisfy the conditions for financial contribution by the Community to common measures within the meaning of Article 8 of Directive 72/161/EEC. This Decision is addressed to the Kingdom of Belgium.
Example Output:
Decision